BRIEF-Regeneron's drug for respiratory virus fails late-stage study
August 14, 2017 at 09:25 AM EDT
* Regeneron to discontinue development of suptavumab for respiratory syncytial virus
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.